US BIS: CCL Clarification of ECCN 1C991 Scope for Vaccines and Medical Products (June 2019 Australia Group Plenary)

Mechanism

ECCN 1C991 controls vaccines, immunotoxins, and medical products that contain or are designed to produce biological agents listed in ECCN 1C351 (human and animal pathogens and toxins), 1C352 (animal pathogens), 1C353 (genetic elements), or 1C354 (plant pathogens). This BIS final rule implements the scope clarifications agreed at the June 2019 Australia Group Plenary Meeting, specifically adding release notes to 1C991 that define the boundary between controlled medical products and those excluded from the most restrictive licensing requirements.

The Australia Group is a multilateral export control regime with approximately 42 member states (including all major EU economies, the US, UK, Canada, Australia, Japan, and South Korea) that harmonises controls on chemical and biological weapons precursors. Plenary-level decisions bind member states to update their domestic control lists; this BIS final rule is the US implementation of the June 2019 AG agreement on the Human and Animal Pathogens and Toxins for Export Control list as it applies to vaccines.

The clarification distinguishes between:

• Controlled: vaccines and immunotoxins containing or intended to produce live biological

agents listed in 1C351–1C354 that retain pathogenic or toxigenic potential

• Released/excluded: standard vaccines produced by established manufacturing methods where

listed biological agents have been rendered non-pathogenic, attenuated, or inactivated in accordance with recognised safety standards

Downstream implications

• Exporters of vaccines and medical products derived from controlled biological agents gain

clearer regulatory guidance on when an EAR export licence is required; this reduces compliance ambiguity for the pharmaceutical and vaccine manufacturing sectors

• The exclusion notes align US practice with the majority of other Australia Group member states

who had already implemented equivalent clarifications following the 2019 Plenary

• No new countries are added to restricted-destination lists; the rule is scope-clarifying only
• ECCN 1C991 remains a dual-use control and humanitarian-use transactions are still subject to

licence review for embargoed/sanctioned destinations even where the 1C991 release notes apply

Open questions

• Subsequent Australia Group plenary cycles (2021-2022, 2023-2024) have continued to update

the AG Common Control Lists; see the companion BIS final rules for those implementation actions

• The boundary between 1C991 (product-level) and 1C351 (agent-level) controls requires case-by-

case classification for novel mRNA and viral-vector vaccine platforms whose manufacturing processes differ materially from the "standard manufacturing methods" reference